SB 351 forbids private equity groups and hedge funds that invest in physician or dental practices from interfering with clinicians’ professional judgment or exercising specified operational controls over those practices. The bill treats any contract term that grants investors the ability to direct clinical care or take certain managerial powers as void and against public policy.
The measure defines “private equity group” and “hedge fund,” carves out passive investors, banks and other lenders, hospital systems, and public agencies, and preserves certain existing corporate-sale noncompete and confidentiality norms while protecting providers’ ability to compete and comment about quality or business practices. Compliance, transactional counsel, investors, and practice owners will need to revisit deal language and governance arrangements to conform with the statute’s bright-line prohibitions.
At a Glance
What It Does
Imposes two linked constraints: it prohibits investors from interfering in clinical decisionmaking and from exercising a list of managerial powers (for example, owning medical records or making billing decisions). Any contractual provision that would permit those interferences or delegations is void. The law also prevents contracts from barring providers from competing or commenting about the practice after they leave.
Who It Affects
Private equity firms and hedge funds that invest in California physician or dental practices, physician and dental practice owners who negotiate management or sale agreements, management companies, and the lawyers and compliance officers who draft and review those contracts. Lenders, hospitals, and public entities are largely carved out.
Why It Matters
The bill removes a common set of investor governance levers from deals and makes certain operational controls legally unavailable to outside investors, which will change deal structures, allocation of post-sale responsibilities, and valuation assumptions. Transactions that rely on governance-based cost control, centralized billing, or investor-directed staffing practices will need new legal and operational designs to stay compliant.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB 351 starts by defining who counts as a private equity group or hedge fund for the statute’s purposes and then draws explicit exclusions. A person or entity that is merely a passive capital provider is not covered; traditional lenders, bond underwriters, and trustees are excluded; hospitals and hospital systems and public agencies are also omitted.
Those definitions matter because the prohibitions target the described class of investors, not every outside entity with a financial interest in a practice.
The core prohibitions break into two categories. First, the bill bars investors from interfering with professional judgment — the kind of decisions that require a licensed clinician’s training and ethical responsibility, such as ordering diagnostic tests, deciding on referrals or consultations, choosing treatment options and ultimately being responsible for patient care, and setting patient-load or work-hour expectations for clinicians.
Second, the law forbids a set of managerial powers from being exercised by investors or delegated to them: owning or determining the content of patient records, making hiring or firing decisions on clinical competency grounds, setting payer-contracting terms, dictating coding and billing decisions, and approving selection of clinical equipment and supplies.SB 351 makes any contractual language that would allow those interferences or delegations void and unenforceable as against public policy. It also addresses common post-transaction restraints: management or asset-sale contracts cannot include clauses that prevent a provider who leaves from competing with the practice or that bar providers from criticizing or raising concerns about care quality, utilization, ethics, or revenue strategies.
The bill preserves an otherwise valid sale-of-business noncompete but says such contracts cannot function as employment noncompetes for providers.For enforcement and context, the statute states its intent to keep clinical decisionmaking with licensed providers and clarifies that it does not change existing corporate practice-of-medicine/dentistry rules under other state or federal law. It permits unlicensed persons or entities to assist practices in the listed managerial activities only if the licensed clinician retains ultimate responsibility and approval.
The Attorney General is given equitable remedies to enforce violations, including injunctive relief and recovery of legal costs, so noncompliant contracts may be subject to statutory litigation or remedial orders.
The Five Things You Need to Know
The bill’s statutory definitions explicitly exclude passive capital contributors, banks and credit unions, commercial real estate lenders, bond underwriters, trustees, hospitals and hospital systems, and public agencies from the terms “hedge fund” and “private equity group.”, SB 351 prohibits investor ownership of or authority to determine the content of patient medical records — a direct bar to contracts that transfer record control to a nonlicensed investor.
Management or asset-sale contracts may not include clauses that bar providers from competing with the practice after resignation or termination, nor can they silence providers from criticizing or commenting on quality, utilization, ethics, or investor revenue strategies.
The bill preserves an otherwise enforceable sale-of-business noncompete, but it disallows using the statute’s permitted contracts as employee noncompete agreements that would bind providers post-employment.
The Attorney General can seek injunctive relief and other equitable remedies and recover attorney’s fees and costs to enforce the statute against violative contracts or arrangements.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Definitions and carve-outs for private equity and hedge funds
This section sets the scope by defining who qualifies as a ‘hedge fund’ or ‘private equity group’ and then lists narrow exclusions — notably passive investors, traditional lenders, hospitals and hospital-affiliated entities, and public agencies. For deal teams, the definitions will determine whether a fund or ownership vehicle falls under the statute; structuring as a passive limited partner or using conventional lending instruments may preserve noncoverage. The carve-outs mean that many lenders and integrated hospital systems retain existing rights that independent PE/hedge investors would lose under SB 351.
Prohibition on interfering with professional judgment
The statute identifies specific clinical decisions that investors may not interfere with — from diagnostic testing to referrals to ultimate responsibility for patient care — and also bars investor directives on clinicians’ patient volumes and work hours. Practically, this prohibits contractual mechanisms and governance arrangements that channel clinical decisionmaking through investor-appointed managers or performance targets tied to clinical choices.
Ban on specified managerial controls and voiding of offending contract terms
SB 351 lists managerial powers that investors may not exercise, including owning or determining patient record content, controlling hiring/firing based on clinical competency, setting payer-contracting parameters, dictating billing/coding, and approving clinical equipment. The statute renders any contract term enabling those powers void and unenforceable and adds an explicit bar on clauses that prevent providers from competing or speaking about quality or business practices after leaving. Transaction documents therefore must avoid drafting that assigns operational control to investors or embeds post-employment gag/lockout provisions that fall within the prohibition.
Scope, relationship to corporate-practice rules, and consultant exception
The law applies regardless of the physician or dental practice’s corporate form and does not change the existing corporate practice-of-medicine/dentistry doctrines. It also allows unlicensed entities to consult or assist with the listed managerial activities so long as the licensed clinician retains ultimate responsibility and approval. That consultant carve-out preserves common operational support models — billing, IT, or purchasing assistance — but places legal and compliance risk on clinicians to maintain ultimate control and signoff.
Enforcement, remedies, and legislative intent
The Attorney General may seek injunctive relief and other equitable remedies and recover attorney’s fees and costs for violations, signaling state-level enforcement capacity rather than a pure private-right-of-action approach. The statute expressly frames its purpose as protecting clinical decisionmaking from nonlicensed investors, which will guide courts interpreting ambiguous provisions and reviewing the voidability of contract clauses.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Physicians and dentists: The statute preserves clinical autonomy by removing investor levers that could direct diagnostic, referral, treatment, and workload decisions, and it protects departing providers’ ability to compete or raise concerns.
- Patients: Indirect beneficiaries because the law is designed to keep clinical decisionmaking with licensed clinicians and reduce financial incentives that could otherwise influence care choices.
- Practice-level compliance and HR teams: Clear statutory prohibitions make it easier to audit agreements and weed out illegal contract provisions during M&A or management transitions.
Who Bears the Cost
- Private equity firms and hedge funds investing in physician/dental practices: They lose certain governance and operational controls commonly used to standardize care, centralize billing, and pursue efficiency targets, which may reduce expected returns or change deal structures.
- Practice sellers and management companies that relied on investor-imposed operational levers: They may need to rework post-closing management, billing, and staffing arrangements and potentially accept lower up-front valuations.
- Deal counsel and contract drafters: Must redesign templates, warranties, and transition services to avoid prohibited powers and to craft acceptable noncompetes and confidentiality language within the statute’s limits.
Key Issues
The Core Tension
The central tension is between protecting clinical autonomy from profit-driven managerial control and allowing investors to structure deals and manage business operations that can improve efficiency or preserve financially at-risk practices; the statute resolves that tension by prioritizing clinical decisionmaking, but at the cost of removing governance tools investors commonly use to realize value or stabilize operations.
SB 351 draws bright lines around investor control but leaves several practical questions for courts and regulators. The statute prohibits investors from ‘interfering with professional judgment’ and from exercising enumerated powers, but it does not provide a detailed interpretive framework for borderline arrangements where investors influence nonclinical business metrics that indirectly affect care.
For example, performance incentives tied to utilization or revenue could be framed as business metrics rather than direct clinical commands; whether those incent structures violate the law will turn on factual inquiries and legal interpretation.
Another implementation challenge is the statute’s broad definitions of private equity groups and hedge funds contrasted with their carve-outs. Investors can restructure securities, use multiple entities, or rely on retained rights through service agreements to achieve operational influence while avoiding the statutory label.
The consultant exception preserves many operational models but shifts legal exposure to clinicians who must retain and document ultimate control — a compliance burden with uncertain boundaries. Finally, enforcing voidability through Attorney General action creates state-level policing but leaves open how quickly courts will unwind complex, closed transactions or what remedial orders will look like in deals involving third-party lenders or multi-tier ownership.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.